EMA starts drawing lines around external control arms
Amsterdam is finally writing down what counts as a credible non-randomised comparator, just as a year of methods papers shows how often submissions still skip the basics.
Regulatory
Dataset-JSON, USDM and IDMP arrive in the same quarter
The XPT transport, the document-shaped protocol and the unstructured product dictionary are all being replaced at once — and the migration paths do not line up.
Pfizer's $10B Innovent bet meets the China-data reckoning
A $10B Pfizer-Innovent pact, a House bill to sweep biotech into COINS, and two China-only ASCO plenaries land in one week — and the bridging-study question is suddenly on the critical path.
FDA opens the door to platform borrowing in genome editing
CBER's draft guidance on "prior knowledge" lands the same week three in vivo cell and gene readouts make the question of borrowing unavoidable. Comments close September 1.
The evidence-synthesis stack is being rebuilt, all at once
An arXiv preprint hands clustering decisions to an LLM while a cluster of new JCE papers concedes that GRADE, PRISMA-P, and guideline appraisal each need patching. The substrate under every HTA dossier is moving.
FDA says yes to R, no to your Docker image
Pilot 4's review letter, J&J's hybrid pipeline, and a Pinnacle 21 gap together draw the real 2026 boundary between what R submissions can do and what reviewers can actually open.
TEMPO lands while wearable endpoints still wobble
FDA wants real-world performance data on digital health devices via a CMS-linked pilot — at the same moment its own wellness exemption let unvetted blood-pressure and glucose features ship to consumers.